Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Olaparib in Recurrent IDH-mutant High Grade Gliomas OLAGLI

NCT03561870 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT03561870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03561870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Olaparib in Recurrent IDH-mutant High Grade Gliomas OLAGLI
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2019
Completion date
November 24, 2021
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mutant high grade glioma, recurrent idh